Literature DB >> 28349724

Loperamide metabolite-induced cardiomyopathy and QTc prolongation.

Zabeer Bhatti1, Jessica Norsworthy1, Tamas Szombathy1.   

Abstract

Loperamide is an over-the-counter, peripherally acting, μ-opioid receptor agonist used for the treatment of diarrhea. In recent times users have found that at higher doses, loperamide crosses the blood-brain barrier and reaches central μ-receptors in the brain, leading to central opiate effects including euphoria and respiratory depression. We report a case of a 37-year-old female who attempted suicide with over 200 loperamide tablets. During her overdose, her QTc was significantly prolonged at >600 ms. Our case aims to add to the growing body of literature describing life-threatening ventricular arrhythmias associated with loperamide toxicity and further suggests that a metabolite of loperamide, desmethylloperamide, may play a role in the pathogenesis.

Entities:  

Keywords:  Loperamide toxicity; complications of poisoning; desmethylloperamide

Mesh:

Substances:

Year:  2017        PMID: 28349724     DOI: 10.1080/15563650.2017.1304555

Source DB:  PubMed          Journal:  Clin Toxicol (Phila)        ISSN: 1556-3650            Impact factor:   4.467


  4 in total

Review 1.  Loperamide cardiotoxicity: "A Brief Review".

Authors:  Tamer Akel; Soad Bekheit
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-11-10       Impact factor: 1.468

2.  Left Ventricular Regional Wall Motion Abnormality in the Setting of Acute Loperamide Overdose.

Authors:  Kasha Bornstein; Timothy Montrief; Mehruba Anwar Parris
Journal:  Clin Pract Cases Emerg Med       Date:  2019-07-01

Review 3.  Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review.

Authors:  Fabrizio Schifano; Stefania Chiappini; John M Corkery; Amira Guirguis
Journal:  Brain Sci       Date:  2018-04-22

4.  Is there such a thing as a 'lope' dope? Analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports.

Authors:  Fabrizio Schifano; Stefania Chiappini
Journal:  PLoS One       Date:  2018-10-04       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.